DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mycobacterium Avium-intracellulare Infection; HIV Infections

Intervention: Clofazimine (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of California, San Francisco

Summary

This study will examine the effectiveness of clofazimine in the prophylaxis of Mycobacterium avium complex infection in HIV infected individuals who are at risk to develop this untreatable opportunistic disease. In the absence of truly effective antiretroviral therapy, a potential mode of treatment of patients with HIV infection is to prevent the development of the life-threatening opportunistic infections. Current studies demonstrate a possible efficacy of clofazimine in the prophylaxis against Pneumocystis carinii pneumonia (PCP), the most common AIDS-defining opportunistic infection. Future studies will examine the potential for prophylaxis against the other opportunistic infections. This proposal hopes to define the role of prophylactic clofazimine in preventing the currently untreatable Mycobacterium avium complex infection. AMENDED: To include prophylaxis for Asymptomatic and ARC.

Clinical Details

Official title: A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

Study design: Primary Purpose: Treatment

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria Concurrent Medication: Allowed:

- Pneumocystis prophylaxis.

- Antiretroviral therapy, or other experimental protocols.

- Antipyretics and analgesics as per the treating physician.

Exclusion Criteria Co-existing Condition: Patients with the following are excluded:

- Unexplained fever.

- Night sweats.

- Unexplained anemia with hemoglobin < 10 g percent or hematocrit less than 30 percent.

- Hepatic transaminase elevations or total bilirubin values of > 3 times normal.

- Long-term (over 2 weeks) treatment with any drug with known significant

anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Patients with the following are excluded:

- Known hypersensitivity to clofazimine.

- Mycobacterium avium complex (MAC) infection diagnosis at any site (except isolation

from stool in asymptomatic patient).

- Any of the following symptoms at the time of study entry:

- Unexplained fever.

- Night sweats.

- Unexplained anemia with hemoglobin < 10 percent or hematocrit less than 30 percent.

- Hepatic transaminase elevations or total bilirubin values of > 3 times normal.

- Long-term (over 2 weeks) treatment with any drug with known significant anti-MAC

activity. Prior Medication: Excluded:

- Long-term (over 2 weeks) treatment with any drug with known significant

anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Group 1:

- AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) within 2

to 4 months prior to study entry.

- Group 2:

- Patients with T4 counts < 100 cells/mm3, regardless of prior opportunistic infections

or malignancies.

- Karnofsky = or > 70.

- All patients must sign informed consent.

Locations and Contacts

Keith Med Group, Los Angeles, California 90048, United States

San Francisco Gen Hosp, San Francisco, California 941102859, United States

Additional Information

Related publications:

Gustavson LE, Fukuda EK, Rubio FA, Dunton AW. A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex. J Acquir Immune Defic Syndr. 1990;3(1):28-31.

Abrams DI, Mitchell TF, Child CC, Shiboski SC, Brosgart CL, Mass MM. Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis. 1993 Jun;167(6):1459-63.


Last updated: June 23, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017